{
    "clinical_study": {
        "@rank": "131043", 
        "arm_group": {
            "arm_group_label": "Thoracic Reirradiation Registry", 
            "description": "Data collection on patients being treated with thoracic reirradiation with PBT or IMRT for NSCLC, with or without chemotherapy."
        }, 
        "brief_summary": {
            "textblock": "The goal of this research study is to learn more about the safety of treating NSCLC with\n      reirradiation using standard methods and to look for ways to lessen side effects and improve\n      therapy.  Reirradiation is when radiation is given to an area of the body that has\n      previously received a full dose of radiation."
        }, 
        "brief_title": "Reirradiation Registry Study", 
        "condition": "Non-Small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "If you agree to take part in this study, data will be recorded during your therapy.  The\n      data to be recorded will include your medical history, the disease, treatments you have\n      received and how you have responded to any treatments, as well as any side effects you may\n      have had.\n\n      The data will be stored on a password-protected computer at MD Anderson for use in future\n      research related to cancer.\n\n      Your data will be given a code number.  No identifying information will be directly linked\n      to your data.  Only the researcher in charge of this study will have access to the code\n      numbers and be able to link the data to you.  This is to allow medical information related\n      to your data to be updated as needed.  Other researchers using your data will not be able to\n      link this data to you.\n\n      Length of Study After you sign this consent form, your active participation on this study\n      will be over.\n\n      This is an investigational study.\n\n      Up to 60 patients will take part in this study.  All will be enrolled at MD Anderson."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        3.1.1 History of previous histologically or cytologically documented NSCLC, stage I-IV.\n\n        3.1.2 Prior course of radiation therapy or concurrent chemoradiation at least 1 month\n        prior to the current course of radiation therapy.\n\n        3.1.3 Patients eligible to receive a second course of radiation therapy to the thorax, at\n        the discretion of the treating physician.\n\n        3.1.4 Patients receiving concurrent chemotherapy or targeted agents will be eligible for\n        this protocol.\n\n        Exclusion Criteria:\n\n        3.2.1 Life expectancy <3 months 3.2.2 Pregnancy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients being treated with thoracic reirradiation with PBT or IMRT for NSCLC, with or\n        without chemotherapy at UT MD Anderson Cancer Center in Houston, Texas."
            }
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01808677", 
            "org_study_id": "PA11-1193"
        }, 
        "intervention": {
            "arm_group_label": "Thoracic Reirradiation Registry", 
            "description": "Data collected in the registry includes patient characteristics/demographics, disease characteristics, treatment details (radiation, chemotherapy, surgery, etc.), toxicity rates, and survival outcomes.", 
            "intervention_name": "Thoracic Reirradiation Registry", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Non-Small Cell Lung Cancer", 
            "NSCLC", 
            "Thoracic reirradiation", 
            "Proton beam therapy", 
            "PBT", 
            "Intensity modulated radiation therapy", 
            "IMRT", 
            "Registry", 
            "Data"
        ], 
        "lastchanged_date": "March 7, 2014", 
        "link": {
            "description": "University of Texas  MD Anderson Cancer Center Website", 
            "url": "http://www.mdanderson.org"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Houston", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "77030"
                }, 
                "name": "UT MD Anderson Cancer Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Registry Study of Thoracic Reirradiation for Non-Small Cell Lung Cancer (NSCLC) Utilizing Proton Beam Therapy or Intensity Modulated Radiation Therapy", 
        "overall_contact": {
            "last_name": "Daniel Gomez, MD", 
            "phone": "713-563-2300"
        }, 
        "overall_official": {
            "affiliation": "UT MD Anderson Cancer Center", 
            "last_name": "Daniel Gomez, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Primary objective to assess the prevalence of high-grade toxicity in patients being treated with thoracic reirradiation with proton beam therapy (PBT) or intensity modulated radiation therapy (IMRT) for non-small cell lung cancer (NSCLC), with or without chemotherapy.  High-grade toxicity defined as CTCAE v4.0 Grade 3 or higher toxicity, or CTCAE v4.0 grade 4 or higher toxicity of the esophagus. Data collected from 1/2/2012 to 1/31/2017.  High-grade toxicity rate and its corresponding 95% confidence interval provided at end of study.  Logistic regression model used to assess the association between prognostic factors such as total dose to normal tissue structures, time since initial course of RT, failure in same lobe of the lung, failure in nodal regions, and central vs. peripheral location and high-grade toxicity.", 
            "measure": "Prevalence of High-Grade Toxicity", 
            "safety_issue": "No", 
            "time_frame": "5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01808677"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "M.D. Anderson Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "M.D. Anderson Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "5 Years", 
        "verification_date": "March 2014"
    }
}